HPV 52 L1 Codon Optimization for Yeast Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccine development is hindered by difficulties in obtaining high expression levels of capsid proteins in transformed host organisms, limiting the production of purified HPV L1 protein for HPV 52, which is essential for effective immunity against HPV infections.
Innovation Solution
Codon-optimized synthetic polynucleotides encoding the HPV 52 L1 protein are designed for high-level expression in yeast cells, eliminating transcription termination signals recognized by yeast, allowing for the production of HPV 52 virus-like particles (VLPs) for use in vaccines and immunogenic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type HPV 52 L1 nucleotide sequences are used for expression in yeast, then the vaccine can be developed, but the expression levels of capsid proteins remain low
Solution Approach 1:
The nucleotide sequence parameters of the HPV 52 L1 gene were optimized by codon optimization to match yeast host preferences, changing the genetic code parameters without altering the amino acid sequence. This resolves the contradiction by improving protein expression levels (productivity) while maintaining the same immunogenic protein product (reliability/vaccine efficacy).
Solution Approach 2:
Specific regions of the nucleotide sequence were modified to eliminate transcription termination signals that are recognized by yeast, while preserving the overall gene structure and function. This local optimization of sequence quality enables continuous transcription and higher protein expression without compromising the vaccine's immunological effectiveness.
2Productivity
If transcription termination signals are eliminated to improve expression, then capsid protein production increases, but the nucleotide sequence becomes more complex
Solution Approach 1:
The nucleotide sequence underwent parameter optimization through codon optimization and removal of transcription termination signals. This transforms the sequence from a simple wild-type copy to an engineered version with modified codon usage patterns and eliminated stop signals, increasing complexity but enabling high-level protein production. The complexity is justified by the substantial gain in productivity.
Data Source
AI summary
Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.